Daniel Vlock

Chief Executive Officer at ALOPEXX, INC.

74 year

Health Technology

Consumer Services

Retail Trade

Profile

Dr. Daniel R.
Vlock, MD, is a Chief Medical Officer at TransCode Therapeutics, Inc., a Chairman & Chief Executive Officer at Alopexx Enterprises LLC, a Chairman, President & Chief Executive Officer at Alopexx, Inc., a Chief Executive Officer at Alopexx Pharmaceuticals LLC, a Chairman at Valerion Therapeutics LLC and a President & Chief Executive Officer at Alopexx Vaccines LLC.
Dr. Vlock was previously employed as a Vice President-Clinical Research by ARIAD Pharmaceuticals, Inc., a Principal by Boehringer Ingelheim Corp., a Principal by Ethicon Endo-Surgery, Inc., a Principal by GPC Biotech, Inc., a Faculty Member by Harvard Medical School, a Principal by Pharmacia Corp., a Faculty Member by University of Pittsburgh School of Medicine, and a Faculty Member by Yale University.
He also served on the board at Kolltan Pharmaceuticals, Inc. He received his undergraduate degree from Cornell University and a doctorate degree from Baylor College of Medicine.

Daniel Vlock active positions

Companies	Position	Start
ALOPEXX, INC.	Chief Executive Officer	31/12/2020
TRANSCODE THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	27/03/2024
Valerion Therapeutics LLC Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Develops targeted therapies for orphan genetic diseases	Chairman	-
Alopexx Vaccines LLC	Chief Executive Officer	-
Alopexx Enterprises LLC Alopexx Enterprises LLC BiotechnologyHealth Technology Engages in investing and managing health care companies	Chief Executive Officer	31/12/2005
Alopexx Pharmaceuticals LLC Alopexx Pharmaceuticals LLC Aerospace & DefenseElectronic Technology Part of Alopexx Enterprises LLC, Alopexx Pharmaceuticals LLC is a biotechnology company based in MA. Alopexx Pharmaceuticals LLC specializes in the development of immune therapeutics for microbial diseases. Founded in 2011 by Daniel R. Vlock, Alopexx focuses on creating broad-spectrum immune approaches to prevent and treat bacterial, fungal, and parasitic infections. The company's technology targets the surface polysaccharide, poly N-acetyl glucosamine (Pnag), which is present on over 75 distinct pathogens. Alopexx's product pipeline includes a fully human monoclonal antibody, F598, and a vaccine candidate, Av0328, both of which have shown promising results in clinical trials. The company aims to reduce the reliance on antibiotics by developing therapies that utilize the host's immune system, thereby preventing the development of antibiotic resistance. Daniel R. Vlock has been the CEO since incorporation.	Chief Executive Officer	30/09/2011

All active positions of Daniel Vlock

Former positions of Daniel Vlock

Companies	Position	End
GPC Biotech, Inc. GPC Biotech, Inc. Drugstore ChainsRetail Trade Develops anticancer drugs	Corporate Officer/Principal	-
ARIAD PHARMACEUTICALS, INC.	Chief Tech/Sci/R&D Officer	-
Kolltan Pharmaceuticals, Inc. Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures monoclonal antibody drugs	Director/Board Member	-
░░░░░░░░░ ░░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	-
░░░░░░░ ░░░░░░░░░░░░░ ░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	-

See the detail of Daniel Vlock's experience

Training of Daniel Vlock

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Daniel Vlock's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	17
ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer	Health Technology
Kolltan Pharmaceuticals, Inc. Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures monoclonal antibody drugs	Health Technology
GPC Biotech, Inc. GPC Biotech, Inc. Drugstore ChainsRetail Trade Develops anticancer drugs	Retail Trade
Pharmacia Corp. Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Researches, manufactures and sells pharmaceuticals	Health Technology
Ethicon Endo-Surgery, Inc. Ethicon Endo-Surgery, Inc. Medical SpecialtiesHealth Technology Manufactures surgical devices and equipments	Health Technology
Yale University Yale University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Cornell University Cornell University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Baylor College of Medicine Baylor College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Boehringer Ingelheim Corp. Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets health care products	Health Technology
Harvard Medical School Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Valerion Therapeutics LLC Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Develops targeted therapies for orphan genetic diseases	Health Technology
Alopexx Pharmaceuticals LLC Alopexx Pharmaceuticals LLC Aerospace & DefenseElectronic Technology Part of Alopexx Enterprises LLC, Alopexx Pharmaceuticals LLC is a biotechnology company based in MA. Alopexx Pharmaceuticals LLC specializes in the development of immune therapeutics for microbial diseases. Founded in 2011 by Daniel R. Vlock, Alopexx focuses on creating broad-spectrum immune approaches to prevent and treat bacterial, fungal, and parasitic infections. The company's technology targets the surface polysaccharide, poly N-acetyl glucosamine (Pnag), which is present on over 75 distinct pathogens. Alopexx's product pipeline includes a fully human monoclonal antibody, F598, and a vaccine candidate, Av0328, both of which have shown promising results in clinical trials. The company aims to reduce the reliance on antibiotics by developing therapies that utilize the host's immune system, thereby preventing the development of antibiotic resistance. Daniel R. Vlock has been the CEO since incorporation.	Electronic Technology
University of Pittsburgh School of Medicine University of Pittsburgh School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Alopexx Enterprises LLC Alopexx Enterprises LLC BiotechnologyHealth Technology Engages in investing and managing health care companies	Health Technology
TransCode Therapeutics, Inc. TransCode Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes diagnostics and therapeutics for the detection and treatment of cancer	Health Technology
Alopexx Vaccines LLC
Alopexx, Inc. Alopexx, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company which develops novel and broad-spectrum immune-mediated therapeutics	Health Technology